Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 17/20 | 0.64 |
| ▸ | ACE | P12821 | 6/20 | 0.64 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.45 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.44 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12481247 | 1.00 | MME (0.64) | MMEACEACE2SRRPSAT1 | |
| SCHEMBL12481241 | 1.00 | MME (0.64) | MMEACEACE2SRRPSAT1 | |
| SCHEMBL12481244 | 1.00 | MME (0.64) | MMEACEACE2SRRPSAT1 | |
| SCHEMBL11994301 | 0.88 | MME (0.54) | MMEACEACE2SRRPSAT1 | |
| SCHEMBL18800933 | 0.88 | MME (0.69) | MMEACE | |
| SCHEMBL19600285 | 0.88 | MME (0.60) | MMEACE | |
| SCHEMBL11969672 | 0.88 | MME (0.69) | MMEACE | |
| SCHEMBL15467558 | 0.88 | MME (0.60) | MMEACE | |
| SCHEMBL15564013 | 0.88 | MME (0.60) | MMEACE | |
| SCHEMBL15466745 | 0.87 | MME (0.68) | MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| US-11919888-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-11547687-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| US-11547687-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| US-20130261316-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130209505-A1 | CRYSTALLINE FORM OF (2S,4R)-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-4-[(1H-[1,2,3]TRIAZOLE-4-CARBONYL)-AMINO]-PENTANOIC ACID 5-METHYL-2-OXO-[1,3]DIOXOL-4-YLMETHYL ESTER | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-08-15 | — | — | US | disclosed |
| US-20130209505-A1 | CRYSTALLINE FORM OF (2S,4R)-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-4-[(1H-[1,2,3]TRIAZOLE-4-CARBONYL)-AMINO]-PENTANOIC ACID 5-METHYL-2-OXO-[1,3]DIOXOL-4-YLMETHYL ESTER | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-08-15 | — | — | US | disclosed |
| US-8481044-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| WO-2013067163-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-02 | — | — | US | disclosed |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-02 | — | — | US | disclosed |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-02 | — | — | US | disclosed |
| US-20120213806-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| WO-2012112742-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885ACE2 13/4885 |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885ACE2 13/4885 |
| US-11547687-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885ACE2 13/4885 |
| US-20120213806-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885ACE2 24/4885 |
| US-20130209505-A1 | CRYSTALLINE FORM OF (2S,4R)-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-4-[(1H-[1,2,3]TRIAZOLE-4-CARBONYL)-AMINO]-PENTANOIC ACID 5-METHYL-2-OXO-[1,3]DIOXOL-4-YLMETHYL ESTER | UACA, CYP4B1, FFAR4 | MME 1982/4885ACE 295/4885ACE2 278/4885 |
| US-20130261316-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885ACE2 24/4885 |
| US-11634413-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885ACE2 18/4885 |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885ACE2 18/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885ACE2 13/4885 |
| US-11919888-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885ACE2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.